Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Boston Scientific Corp (NYSE: BSX) closed the day trading at $97.72 down -0.86% from the previous closing price of $98.57. In other words, the price has decreased by -$0.86 from its previous closing price. On the day, 9.41 million shares were traded. BSX stock price reached its highest trading level at $99.23 during the session, while it also had its lowest trading level at $97.15.
Ratios:
For a better understanding of BSX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 105.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 37.88. For the most recent quarter (mrq), Quick Ratio is recorded 0.96 and its Current Ratio is at 1.51. In the meantime, Its Debt-to-Equity ratio is 0.51 whereas as Long-Term Debt/Eq ratio is at 0.49.
On September 08, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $125.
On June 16, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $118.Leerink Partners initiated its Outperform rating on June 16, 2025, with a $118 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Butcher Arthur C sold 17,313 shares for $101.55 per share. The transaction valued at 1,758,189 led to the insider holds 23,600 shares of the business.
ARTHUR C BUTCHER bought 17,313 shares of BSX for $1,758,188 on Dec 01 ’25. On Nov 06 ’25, another insider, Zane Ellen M, who serves as the Director of the company, sold 12,891 shares for $98.28 each. As a result, the insider received 1,266,978 and left with 24,134 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BSX now has a Market Capitalization of 144864231424 and an Enterprise Value of 155870232576. As of this moment, Boston’s Price-to-Earnings (P/E) ratio for their current fiscal year is 52.27, and their Forward P/E ratio for the next fiscal year is 28.16. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.23. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.49 while its Price-to-Book (P/B) ratio in mrq is 6.19. Its current Enterprise Value per Revenue stands at 8.056 whereas that against EBITDA is 30.738.
Stock Price History:
The Beta on a monthly basis for BSX is 0.67, which has changed by 0.09437108 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, BSX has reached a high of $109.50, while it has fallen to a 52-week low of $85.98. The 50-Day Moving Average of the stock is -1.52%, while the 200-Day Moving Average is calculated to be -3.70%.
Shares Statistics:
Over the past 3-months, BSX traded about 9.53M shares per day on average, while over the past 10 days, BSX traded about 9561340 shares per day. A total of 1.48B shares are outstanding, with a floating share count of 1.48B. Insiders hold about 0.39% of the company’s shares, while institutions hold 93.38% stake in the company. Shares short for BSX as of 1763078400 were 21076004 with a Short Ratio of 2.21, compared to 1760486400 on 19634328. Therefore, it implies a Short% of Shares Outstanding of 21076004 and a Short% of Float of 1.4199998999999999.
Earnings Estimates
Boston Scientific Corp (BSX) is presently subject to a detailed evaluation by 27.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.79, with high estimates of $0.85 and low estimates of $0.75.
Analysts are recommending an EPS of between $3.07 and $2.98 for the fiscal current year, implying an average EPS of $3.03. EPS for the following year is $3.47, with 32.0 analysts recommending between $3.62 and $3.35.
Revenue Estimates
26 analysts predict $5.28B in revenue for. The current quarter. It ranges from a high estimate of $5.33B to a low estimate of $5.25B. As of. The current estimate, Boston Scientific Corp’s year-ago sales were $4.56BFor the next quarter, 26 analysts are estimating revenue of $5.2B. There is a high estimate of $5.31B for the next quarter, whereas the lowest estimate is $5.12B.
A total of 31 analysts have provided revenue estimates for BSX’s current fiscal year. The highest revenue estimate was $20.23B, while the lowest revenue estimate was $20.03B, resulting in an average revenue estimate of $20.08B. In the same quarter a year ago, actual revenue was $16.75BBased on 32 analysts’ estimates, the company’s revenue will be $22.37B in the next fiscal year. The high estimate is $23.86B and the low estimate is $22.01B.
